ArticleThe Journal of allergy and clinical immunology2026
Characterization of missense variants in the signal peptide of C1 esterase inhibitor.
Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHereditary angioedema with C1 esterase inhibitor (C1INH) deficiency is caused by variants in the SERPING1 gene. A decrease in C1INH function results in overproduction of bradykinin, causing enhanced vascular permeability and swelling. Signal peptide (SP) is essential for C1INH secretion. While SP variants in the SERPING1 gene have been reported, their genotype-phenotype correlations have not been well characterized.
objectiveTo investigate the impact of SP variants, we systematically evaluated 33 SP variants of C1INH by examining their expression, function, and intracellular location.
methodsThe SP variants were transiently transfected into 293T cells. Their concentration was compared to wild-type C1INH. Functional analyses were performed by assessing their binding with activated C1s, kallikrein, and factor XIIa. Transfected HeLa cells were used to assess the intracellular localization of C1INH variants.
resultsOf 33 SP variants, 6 were poorly synthesized. Among these, 3 are in the H region (L10R, L12R, L13-L15del) and 3 are in the C-terminal region (G17R, A20D, S22L). Compared to wild type, the remaining variants demonstrated normal recombinant protein expression and intact binding activity to their substrates. Protein aggregates were observed in the endoplasmic reticulum of L10R-, G17R-, and S22L-transfected cells.
conclusionsThe H- and C-terminal regions of SP are critical for C1INH production. Shortening or introducing positive charges into the hydrophobic core of the H-terminal region can lead to pathogenic consequences. Disrupting the SP cleavage site in the C-terminal region impairs protein production. This study provides new insights into the impact of SP variants on C1INH expression leading to hereditary angioedema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.